Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-01 17:45 |
Nombre de droits de vote au 31 janvier 2024
|
French | 119.9 KB | ||
| 2024-01-31 07:30 |
Nicox : Prolongation de 5 ans de la durée d’un brevet américain couvrant le lat…
|
French | 190.8 KB | ||
| 2024-01-31 07:30 |
Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for …
|
English | 173.0 KB | ||
| 2024-01-25 07:30 |
Nicox : Résumé financier et point d’activité du quatrième trimestre 2023
|
French | 246.6 KB | ||
| 2024-01-25 07:30 |
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
|
English | 229.1 KB | ||
| 2024-01-08 07:30 |
Nicox : Bilan semestriel du contrat de liquidité avec Kepler Cheuvreux au 31 dé…
|
French | 287.2 KB | ||
| 2024-01-08 07:30 |
Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of Dece…
|
English | 249.1 KB | ||
| 2024-01-03 07:30 |
Nicox : Termination of the liquidity contract with Kepler Cheuvreux
|
English | 166.4 KB | ||
| 2024-01-03 07:30 |
Nicox : Résiliation du contrat de liquidité avec Kepler Cheuvreux
|
French | 160.5 KB | ||
| 2024-01-02 17:45 |
Nombre de droits de vote au 31 décembre 2023
|
French | 119.8 KB | ||
| 2024-01-02 17:45 |
Number of voting rights as of December 31, 2023
|
English | 119.9 KB | ||
| 2023-12-18 07:30 |
Nicox : Pré-sélection du premier patient dans l’étude de phase 3b Whistler sur …
|
French | 166.8 KB | ||
| 2023-12-18 07:30 |
Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 47…
|
English | 171.5 KB | ||
| 2023-12-14 07:30 |
Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effect…
|
English | 171.2 KB | ||
| 2023-12-14 07:30 |
Nicox : Publication de nouvelles données non cliniques sur le NCX 470 démontran…
|
French | 204.5 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
